BiotechTube
Home/Pipeline/Personalized Cancer Immunotherapy Program

Personalized Cancer Immunotherapy Program

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication
Oncology (unspecified)
Phase
Pre-clinical
Status
Active
Company
NEC Bio

About NEC Bio

NEC Bio is a Munich-based biotech leveraging NEC's extensive IT and AI expertise to innovate in oncology drug discovery and development. As a subsidiary of a large public corporation, it operates with strategic backing, aiming to translate complex biological data into personalized cancer immunotherapies. The company is positioned at the intersection of big data and life sciences, seeking to improve therapeutic targeting and patient outcomes. Its current status is likely pre-clinical and pre-revenue, focused on platform development and early-stage research programs.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a